HELIVARA Trademark

Trademark Overview


On Wednesday, June 3, 2026, a trademark application was filed for HELIVARA with the United States Patent and Trademark Office. The USPTO has given the HELIVARA trademark a serial number of 99862060. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, June 3, 2026. This trademark is owned by Veloxis Pharmaceuticals, Inc.. The HELIVARA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of physical ailments; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for skin wounds; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for the treatment of burns; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cardiovascular disease and cerebrovascular disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of neurological disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cancer; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of osteoporosis; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of infectious disea...

General Information


Serial Number99862060
Word MarkHELIVARA
Filing DateWednesday, June 3, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, June 3, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of physical ailments; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for skin wounds; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of for the treatment of burns; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cardiovascular disease and cerebrovascular disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of neurological disease; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of cancer; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of osteoporosis; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of infectious diseases; pharmaceutical, peptide, and biologic preparations for the treatment of rheumatism; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of fever blisters; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of autoimmune diseases; pharmaceutical, peptide, and biologic preparations for the treatment of inflammation immunology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of organ transplant; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of pain; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of rare diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of digestive diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of hematologic disorders; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of kidney diseases; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment of disease with immunosuppression; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in urology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in rheumatology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in nephrology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in organ transplant; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in hematology; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in orthopedic medicine; pharmaceutical, peptide, and biologic preparations and substances for the prophylaxis and treatment in pulmonology; drug delivery agents in the form of solutions, compounds, powders, and tablets that facilitate delivery of a wide range of pharmaceuticals, peptides, and biologics

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, June 3, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVeloxis Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCary, NC 27518
US

Trademark Events


Event DateEvent Description
Wednesday, June 3, 2026NEW APPLICATION ENTERED
Wednesday, June 3, 2026APPLICATION FILING RECEIPT MAILED
Wednesday, June 3, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED